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Abstract
Factor H-binding protein (fHbp) is an important meningococcal vaccine antigen. Native
outer membrane vesicles with over-expressed fHbp (NOMV OE fHbp) have been shown to
induce antibodies with broader functional activity than recombinant fHbp (rfHbp). Improved
understanding of this broad coverage would facilitate rational vaccine design. We performed
a pair-wise analysis of 48 surface-exposed amino acids involved in interacting with factor H,
among 383 fHbp variant group 1 sequences. We generated isogenic NOMV-producing
meningococcal strains from an African serogroup W isolate, each over-expressing one of
four fHbp variant group 1 sequences (ID 1, 5, 9, or 74), including those most common
among invasive African meningococcal isolates. Mice were immunised with each NOMV,
and sera tested for IgG levels against each of the rfHbp ID and for ability to kill a panel of het-
erologous meningococcal isolates. At the fH-binding site, ID pairs differed by a maximum of
13 (27%) amino acids. ID 9 shared an amino acid sequence common to 83 ID types. The
selected ID types differed by up to 6 amino acids, in the fH-binding site. All NOMV and rfHbp
induced high IgG levels against each rfHbp. Serum killing from mice immunised with rfHbp
was generally less efficient and more restricted compared to NOMV, which induced antibod-
ies that killed most meningococci tested, with decreased stringency for ID type differences.
Breadth of killing was mostly due to anti-fHbp antibodies, with some restriction according to
ID type sequence differences. Nevertheless, under our experimental conditions, no relation-
ship between antibody cross-reactivity and variation fH-binding site sequence was identi-
fied. NOMV over-expressing different fHbp IDs belonging to variant group 1 induce
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antibodies with fine specificities against fHbp, and ability to kill broadly meningococci
expressing heterologous fHbp IDs. The work reinforces that meningococcal NOMV with OE
fHbp is a promising vaccine strategy, and provides a basis for rational selection of antigen
sequence types for over-expression on NOMV.
Introduction
Neisseria meningitidis is a leading cause of bacterial meningitis worldwide, and recurrent epi-
demics in Sub-Saharan Africa [1, 2]. An important meningococcal virulence factor and vac-
cine antigen is factor H-binding protein (fHbp). fHbp is an outer-membrane surface-exposed
lipoprotein, expressed by almost all meningococcal strains, albeit at varying levels [3–7]. It
binds human factor H (fH), a negative regulator of the alternative pathway of the complement
cascade, allowing meningococci to escape innate immunity [8, 9]. Antibodies directed against
fHbp are bactericidal, and can both activate the complement cascade, and block the recruit-
ment of fH by bacteria [5, 6, 9–13]. fHbp is included in licensed protein-based vaccines against
group B meningococcus [14, 15].
On the basis of amino acid sequence, fHbp is classified into two sub-families (A and B) [10],
or three variant groups (v.1, v.2, v.3) [5]. fHbp can be further divided into more than 1,000 sub-
variants, with each individual amino acid sequence distinguished by an identification number
(ID); the majority of these sub-variants are included in variant group 1, which currently con-
tains 580 IDs, while variant groups 2 and 3 have 215 IDs each. Sera raised against recombinant
fHbp generally are bactericidal against strains expressing fHbp belonging to the same variant
group, with limited cross-reactivity between variant groups. However, fHbp sequence diversity
within each variant group limits breadth of bactericidal activity [3, 5, 6, 10, 16, 17].
Native Outer Membrane Vesicles (NOMV) are membrane blebs that can be shed naturally
by Gram-negative bacteria [18]. Meningococcal detergent-extracted OMV (DOMV) have
been used safely and effectively as vaccines in humans for almost 30 years but provide strain-
specific protection [19, 20]. Previous studies have shown that meningococcal NOMV with
over-expressed (OE) fHbp v.1, induce antibodies in mice with broader bactericidal activity
against African isolates, than antibodies induced by DOMV or recombinant fHbp [21, 22].
However, the specific contribution of the fHbp sequence ID to the cross-reactivity of antibod-
ies induced by NOMV OE fHbp has not been extensively studied.
We did not focus our attention on the entire fHbp protein sequence, as this would have
considered variations at positions not necessarily immunological relevant. However, the fH-
binding region is surface-exposed, and variation is likely to be subjected to a balance between
opposing selection pressures from the human immune system and functional constraints.
Therefore, we performed a comparative analysis of the region of fHbp involved in fH binding,
likely to be an important target for protective antibodies. We studied the specificity and cross-
reactivity of anti-fHbp antibody responses elicited by NOMV over-expressing different fHbp
ID types, by investigating the relationship between the amino acid sequence of this region of
fHbp and the extent of cross-reaction of antibodies induced by NOMV with over-expressed
fHbp. Because a vaccine that can protect against multiple serogroups of N. meningitidis is par-
ticularly needed for Sub-Saharan Africa, we compared cross-reactivity of sera elicited by
NOMV OE different fHbp ID types belonging to variant group 1 (the most prevalent fHbp
variant group among Africa strains [16]), against serogroups of meningococcus that are preva-
lent in Africa.
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Materials and methods
fH-binding site analysis on fHbp
We mapped the residues of fHbp that are in contact with fH on the published crystal structure
of the fHbp v.1-fH complex [23, 24], using the publicly available software Cn3D. Parameters
were set to identify residues on fHbp that are at a maximum distance of 5 Å from the fH mole-
cule, revealing 48 amino acids as points of interaction between fHbp and fH. We aligned the
383 unique fHbp v.1 peptide sequences published on the Neisseria.org database [25], and iden-
tified the 48 amino acids contributing to the fH-binding site on each sequence, using fHbp ID
1 as the reference sequence (S1 Table). To compare the number of different amino acids
between each pair of the 383 IDs, we created a mn matrix in which each cell contains the num-
ber of amino acid differences between sequence m and sequence n (Fig 1 and S2 Table).
Neisseria meningitidis strains and generation of mutants
The parental wild type strain, used for generating N. meningitidis mutants for NOMV produc-
tion, has been described by us previously [21]: it is a serogroup W, ST11 clone, isolated in 2004
in Ghana, expressing fHbp variant group 2 ID 23, and PorA serosubtype P1.5,2 [21]. To gener-
ate mutants over-expressing fHbp v.1, the native fHbp v.2 gene was deleted and replaced by an
erythromycin resistance cassette [5]. The resulting fHbp v.2 KO mutant was subsequently used
to generate a panel of isogenic strains, over-expressing four different fHbp v.1 ID types. fHbp
v.1 genes were amplified by PCR from genomic DNA of different meningococcal strains (ID 1
from MenB MC58; ID 5 from a MenA isolate; ID 9 from a MenW isolate, and ID 74 from a
MenX isolate), with primers as shown in Table 1. The R41S mutation, known to reduce the
human fH binding to fHbp [26], was introduced in the full-length fHbp genes using the Q5
Site-Directed Mutagenesis Kit (NEB), following the manufacturer’s protocol. fHbp genes were
inserted into the group W capsule biosynthesis locus, in the place of synXBCD, under the con-
trol of a strong synthetic promoter [27]. A MenW control strain devoid of both fHbp expres-
sion and capsule biosynthesis was produced by deleting capsule biosynthesis genes in the
MenW fHbp KO mutant, as described before [21].
NOMV preparation
NOMV were prepared as previously described [21]: bacteria were grown at 37˚C, 5% CO2, in
50 mL of medium (containing yeast extract, casaminoacids, and lactic acid), to stationary
phase. Cells were harvested by centrifugation at 4,000 g, and the supernatant was filtered
through a 0.22 μm pore size Stericup (Millipore, Billerica, MA, USA). NOMV were collected
by ultracentrifugation of the filter-sterilized culture supernatant (186,000 g, 2 h, 4˚C, using
Beckman polystyrene tubes). After ultracentrifugation, the NOMV-containing pellet was
resuspended in phosphate buffered saline (PBS), and sterile-filtered through a syringe filter
with 0.22 μm pore size. NOMV concentrations were determined based on the total protein
content, as measured by Lowry assay, in comparison to a standard curve obtained with bovine
serum albumin (BSA) (Sigma-Aldrich, St. Louis, MO, USA) [28]. For protein analysis, NOMV
were separated by SDS–PAGE using NuPAGE 12% Bis-Tris Protein Gels, and NuPAGE
MOPS SDS Running Buffer (Invitrogen, Carlsbad, CA, USA). Total proteins were stained with
Coomassie Blue stain (Sigma-Aldrich). fHbp was detected by Western blot using a polyclonal
antibody raised in mice against recombinant fHbp v.1 ID 1. All the NOMV used in this study
are listed in detail in Table 2.
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Cloning, expression, and purification of recombinant fHbp
The four gene sequences encoding the fHbp ID types over-expressed in the meningococcal
mutants were cloned without the signal peptide sequence, and with a C-terminal hexahisti-
dine-tag, into the expression vector pET21b (Novagen, Madison, WI, US). All four sequences
contained the R41S mutation. Recombinant proteins were expressed and purified from E. coli
BL21(DE3) (Novagen, Madison, WI, US), as described elsewhere [5].
Fig 1. Section of matrix for pairwise comparison of fH-contact residues on fHbp v.1 IDs. Each cellmn contains the number of different
amino acids in the fH-binding site between IDm and IDn. The darkness of shading of each intersection corresponds to the number of
differences, with white = 0 differences. In the table below the matrix, for each IDm the number of fHbp v.1 peptides differing for an increasing
number of amino acids is given, together with the average number of different residues between IDm and all other v.1 peptides. IDs
belonging to v.1 between 12 and 60, and between 80 and 677 are not shown (full matrix available in S2 Table).
https://doi.org/10.1371/journal.pone.0181508.g001
Contribution of fHbp sequence to cross-reactivity of meningococcal NOMV vaccines
PLOS ONE | https://doi.org/10.1371/journal.pone.0181508 July 25, 2017 4 / 21
Biophysical analyses of purified NOMV
NOMV preparations were analysed by HPLC-SEC with a TosoHaas TSK gel 6,000 + 4,000 PW
columns equilibrated in PBS, and with in-line UV, fluorescence emission, and MALS (Dawn
Heleos II, Wyatt) detectors. 80 μL of samples, containing 0.1 mg/mL total protein, were
injected and eluted with a flow rate of 0.5 mL/min in PBS. UV, fluorescence emission, and
multiangle light scattering (MALS) data were collected and analysed using Empower 3 and
ASTRA 6 software (Wyatt Technology). Light scattering analysis was done using “Zimm”
model with fit degree 1.
Dynamic light scattering (dls) measurements were performed with a Malvern Zetasizer
Nano ZS (Malvern, Germany), equipped with a 633-nm He-Ne laser and operating at an angle
of 173˚. The software used for collecting and analysing data was the Setasizer 7.11 from Mal-
vern. 40 μL of each sample were measured in ZEN 0040-disposable micro cuvette (Malvern).
The measurements were done with an automatic attenuator, and at controlled temperature of
25˚C. For each sample, 10–15 runs of 10 s were performed, with 3 repetitions. The intensity
size distribution, the Z-average diameter, and the polydispersity index (PdI) were obtained
from the autocorrelation function using the “general purpose mode”. Default lower threshold
of 0.05 and upper threshold of 0.01 were used. Viscosity and refractive index of PBS at 25˚C
were used for data analysis.
Mouse immunisation
4–6 weeks old female CD-1 mice were obtained from Charles River Laboratories (Wilmington,
MA, USA). Eight mice per group were immunised twice, 4 weeks apart, by intraperitoneal
Table 1. Sequences of primers used in this study.
Purpose Primer designation 50-30 primer sequence
Amplification of up-stream recombination site of capsule biosynthesis locus Cps_upF TCCCCCCGGGTATCGCCAACAAACGGCACAG
Cps_upR GCTCTAGATTTCGATTAAGTGCTATAATTAGGCC
Amplification of down-stream recombination site of capsule biosynthesis locus Cps_doF GCCAATGCATCAATATGCTGCCATTACTCC
Cps_doR GGACTAGTGTTTGTTTGCCGCATGCTAATGCC
Amplification of fHbp ID 1, 5, 74 fHbp_fw CGCGGATCCCATATGAATCGAACTGCCTTCTGCTGCC
fHbp_rev CCATTGTGAAAATGCCGTC
Amplification of fHbp ID 9 ID9_fNde CGCGGATCCCATATGAACCGAACTACCTTTTTCTGCC
fHbp_rev CCATTGTGAAAATGCCGTC
https://doi.org/10.1371/journal.pone.0181508.t001
Table 2. List of NOMV used in this study.
NOMV designation Parental strain Mutations in the NOMV-producing strain Description
NOMV MenA wt* MenA none Native expression of fHbp v.1 ID 5
NOMV MenW wt* MenW none Native expression of fHbp v.2 ID 23
NOMV fHbp KO MenW cps KO; fHbp v.2 KO fHbp KO control
NOMV OE ID 1 MenW cps KO; fHbp v.2 KO; OE fHbp ID 1R41S Over-expression of fHbp ID 1R41S
NOMV OE ID 5 MenW cps KO; fHbp v.2 KO; OE fHbp ID 5R41S Over-expression of fHbp ID 5R41S
NOMV OE ID 9 MenW cps KO; fHbp v.2 KO; OE fHbp ID 9R41S Over-expression of fHbp ID 9R41S
NOMV OE ID 74 MenW cps KO; fHbp v.2 KO; OE fHbp ID 74R41S Over-expression of fHbp ID 74R41S
*NOMV were used as controls in analytical testing
https://doi.org/10.1371/journal.pone.0181508.t002
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injection. Serum samples were obtained from bleeds at 2 and 4 weeks after the first dose, and 2
weeks after the second dose. On the basis of previous studies [16, 21], doses were chosen as fol-
lows: mice were immunised with 1 μg of NOMV OE fHbp (containing 85 ng of fHbp protein),
or 5 μg of NOMV fHbp KO, or 20 μg of recombinant protein. 20 μg of recombinant fHbp is
the dosage selected for a maximum response; 1 μg of NOMV OE fHbp is sufficient to elicit a
potent antibody response [21], but for NOMV fHbp KO we used the higher dose of 5 μg to
enhance the immune response from the negative control. All vaccines were adsorbed on 3 mg/
mL Alhydrogel (Brenntag), in a formulation containing 10 mM Histidine and 0.9 mg/mL
NaCl. Sera were stored at -80˚C until use.
Ethical statement
The animal protocol was approved by the Animal Welfare Body of Novartis Vaccines, Siena,
Italy, and by the Italian Ministry of Health (Approval number AEC201309). The mouse
immunisation experiments were performed at the Toscana Life Sciences (TLS), Siena, Italy,
in compliance with the relevant Italian guidelines (Italian Legislative Decree n.116/1992).
Mice were housed in appropriate plastic cages, and provided with food, water, and wooden
litter. Each cage was maintained in ventilated cabinets with constant air flow and 12 hours of
light per day. Animals were monitored at least twice a day during the study; during the two
days following each immunisation, particular attention was dedicated to signs of good health
and abnormalities at the site of injection. Mice were euthanized with CO2 after
anesthetization.
Serological analysis
Anti-fHbp ID 1, ID 5, ID 9, ID 74 serum IgG antibodies were measured by enzyme-linked
immunosorbent assay (ELISA) as described elsewhere [29]. Each recombinant fHbp ID was
used for ELISA plate coating at a concentration of 1 μg/mL. Mouse sera were diluted 1:100,
1:4,000, or 1:160,000 in PBS containing 0.05% Tween 20 and 0.1% BSA. ELISA units were
expressed relative to a mouse anti-fHbp ID 9 IgG standard curve. One ELISA unit was defined
as the reciprocal of the standard serum dilution that gives an absorbance value of 1 in the
assay; each mouse serum was tested in triplicate on different plates. Data are shown as scatter
plots of the mean of individual mouse ELISA units, and the geometric mean is shown for each
group.
Serum bactericidal antibody response against meningococcal clinical isolates was measured
on individual sera as described before [21]. 20% final concentration of Baby Rabbit Comple-
ment (CEDARLANE, Canada, lot number 6332), screened for lack of bactericidal activity
against the target strains, was used as complement source in the assay; this was chosen instead
of human complement because of the large amount of complement required to test individual
mouse sera. Bactericidal titres were defined as the reciprocal extrapolated serum dilution
resulting in 50% killing of bacteria, after 60 min incubation at 37˚C, compared to the mean
number of bacteria in five control reactions at time 0. Origin and characterisation of the strains
tested are summarized in Table 3.
Statistical analysis
For statistical analysis, SBA titres <10 were assigned the value 1. Pearson’s Correlation test was
used to evaluate linear correlation between two sets of values. Mann–Whitney U test was used
to compare pairs of values. P0.05 was considered statistically significant. Analysis was per-
formed with GraphPad Prism 6 software.
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Results
Pairwise comparison of fHbp-fH contact residues in 383 fHbp v.1
sequence IDs
At the time of the study, 383 fHbp v.1 peptide sequences were available in the public database
(Neisseria.org) [25]. The 48 amino acids identified as contact sites with fH in each of the 383
IDs (S1 Table) were compared by sequence alignment. We created a matrix with the number
of amino acid differences in the fH contact site between each pair of fHbp IDs. A section of
the pairwise comparison matrix is shown in Fig 1 (full matrix in S2 Table). We identified 74
individual sequences of fHbp-fH contact residues; 41 of those (55%) were unique to one
fHbp ID. The most shared fH-binding site sequence was found in 83 out of the 383 peptides
(21.7%) and hence represents a fH-binding site consensus sequence, which we hypothesized
might contribute to the induction of anti-fHbp antibodies with broad ID cross-reactivity. If
one difference at any position in the fH-binding site consensus sequence was allowed, the
number of IDs sharing it increased to 122 (31.9%). The biggest difference in the fH-binding
site between any pair of IDs was 13 amino acids (27.1%), and was found between 8 different
pairs of IDs. The biggest difference compared to the consensus sequence was identified
among 5 fHbp IDs: ID 217 and ID 359 both had 10 amino acid (aa) differences compared to
the consensus sequence (their fH-binding site being identical, and their whole peptide
sequences differing by only one amino acid); ID 120 and ID 215 had 8 aa differences com-
pared to the consensus sequence (their fH-binding site being identical, and their whole pep-
tide sequences differing only in the N-terminal serine/glycine part); ID 55 similarly had 8 aa
differences, compared to the consensus sequence, with its fH-binding sequence being one of
the 41 unique IDs.
Table 3. Characteristics of N. meningitidis strains used in in this study.
Designation Serogroup Year of
isolation
Country CC [ST]a PorA
subtype
fHbp variant group and
IDb
fHbp expression
(%)c
Parent NOMV vaccine
strain
W 2004 Ghana 11 [11] P1.5, 2 v.2, 23 NDd
Test strains for SBA
MenA 1 A 2009 Nigeria 5 [7] P1.20,9 v.1 ID 5 107
MenA 2 A 2006 Burkina
Faso
5 [2859] P1.20,9 v.1 ID 5 52
MenA 3 A 2007 Burkina
Faso
5 [6035] P1.20,9 v.1 ID 5 65
MenW W 2009 Cameroon 175
[2881]
P1.5–1,2–36 v.1 ID 9 1
MenX 1 X 2006 Niger 181 [181] P1.5–1,10–1 v.1 ID 74 75
MenX 2 X 2010 Burkina
Faso
181 [181] P1.5–1,10–1 v.1 ID 74 69
MenC C 2007 Germany NAe [32] P1.7,16 v.1 ID 1 NDc
aCC: Clonal Complex; ST: Sequence Type.
bDetermined by sequencing of the fHbp gene and analysing the protein sequence using the Neisseria.org database [25].
cfHbp expression was measured by Western blot of whole cell lysates and in relation to group B strain H44/76, as previously described [21].
dND: Not Determined.
eNA: Not Assigned.
https://doi.org/10.1371/journal.pone.0181508.t003
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Selection of fHbp IDs for over-expression on NOMV
To investigate whether there is a correlation between the sequence commonality of the fHbp
region involved in binding fH, and the breadth of cross-protection induced by NOMV OE
fHbp, against meningococcal isolates expressing different fHbp IDs, we selected different
fHbp v.1 ID types for over-expression in N. meningitidis NOMV. We selected the fHbp pep-
tides belonging to variant group 1, carrying either the fH-contact consensus sequence, or a less
common sequence, and identified as the most prevalent among African case-related clinical
isolates: ID 5, ID 9, and ID 74 [16, 30]. ID 9 is one of the peptides that contain the fH-binding
site consensus sequence. We further included ID 1 among the peptides not carrying the con-
sensus contact sequence, for comparison with previous work [21]. The fHbp-fH binding resi-
dues of the four selected fHbp ID types were all different from each other (Fig 1). Phylogenetic
trees showing these four IDs in the context of the other 379 full length sequences, as well as of
the other 70 fH-binding sequences, are represented in S1 Fig. fH-contact sequence of ID 1 is
shared by a total of 17 fHbp v.1 peptides (4.4%), the sequence of ID 5 by 33 (8.6%), and
sequence of ID 74 by 7 (1.8%) peptides. Among these four selected ID types, the minimum
number of differences in the fHbp-fH contact sequence was 2 amino acids (4.2%) between ID
1 and ID 5, and between ID 5 and the consensus sequence in ID 9, while the maximum num-
ber of differences was 6 (12.5%), between ID 74 and ID 5, and between ID 74 and the consen-
sus sequence in ID 9. The number of amino acid differences compared with the fH-binding
site consensus sequence for ID 1 was 4 (Fig 1).
Characterisation of NOMV with over-expressed fHbp
NOMV from the strains over-expressing the different fHbp IDs were prepared as described in
the methods section. SDS–PAGE and Coomassie Blue staining revealed similar protein pat-
terns in NOMV preparations from the different engineered meningococcal strains, consistent
with the protein pattern of NOMV from the parental wild type strain (Fig 2A). NOMV from
the mutant strains showed similar average radius of 53–57 nm, and similar size distribution, as
determined by HPLC-SEC/MALS and dls (Table 4), in accordance also with micrographs
obtained by Transmission Electron Microscopy.
Detection of fHbp in NOMV by Western blot, using a mouse polyclonal anti-fHbp v.1 anti-
body, indicated a comparable amount of fHbp present in NOMV from the different mutants
(Fig 2B). This suggests that similar quantities of the four fHbp IDs were used for immunisation
with the different NOMV, which is around 8.5% total protein content, as measured by Selected
Reaction Monitoring (SRM, [7]). Comparison of fHbp levels in NOMV from MenW OE ID 9
and from a wild type MenA strain expressing medium levels of fHbp ID 5, showed that the
level of fHbp detected in 0.05 μg of NOMV from the mutant is higher than that detected in
0.5 μg of NOMV from the wild type MenA (Fig 2C). This suggests that the mutant strains pro-
duce NOMV with more than 10-fold higher amounts of fHbp than this wild type strain.
Anti-fHbp antibody response as analysed by ELISA
To investigate the specificity and cross-reactivity of the anti-fHbp antibody response induced
by NOMV OE the four diverse fHbp sequences, we compared IgG antibody levels against dif-
ferent recombinant fHbp ID types, in single mouse sera from different immunisation groups.
Mice were immunised with either 1 μg of NOMV over-expressing one of the four fHbp ID
types selected (ID 1, ID 5, ID 9, or ID 74), or 5 μg of NOMV without fHbp (NOMV fHbp KO),
or 20 μg of one of the four recombinant fHbp IDs. By ELISA, we measured anti-fHbp IgG anti-
bodies in single sera obtained 2 and 4 weeks after the first dose, and 2 weeks after the second
dose (antibody levels at 2 weeks post second dose are shown in Fig 3). The antibodies present
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in each serum sample were measured against each of the four fHbp ID types used for
immunisation.
Sera from mice immunised with NOMV without fHbp had no detectable anti-fHbp
response (Fig 3A). NOMV OE ID 1 induced anti-fHbp IgG antibodies that were significantly
higher when measured against the homologous ID, than against the three heterologous fHbp
peptides (Fig 3B). NOMV OE ID 9 and NOMV OE ID 74 elicited high IgG antibody levels
that were not significantly different when measured against the respective homologous fHbp
IDs and fHbp ID 1, (Fig 3D and 3E). NOMV OE ID 5 induced IgG antibody levels against the
homologous ID 5 and against heterologous ID 1 and ID 9 that were not significantly different.
Altogether these data suggest that NOMV OE the different fHbp sequences induce a range of
anti-fHbp IgG which collectively are able to bind the homologous and heterologous fHbp pep-
tides, with NOMV OE ID 5 having reduced specificity compared to the others.
Fig 2. NOMV characterisation. (A) SDS-PAGE and Coomassie staining of NOMV. Samples: NOMV from MenW wild type;
NOMV OE ID 1; NOMV OE ID 5; NOMV OE ID 9; NOMV OE ID 74; NOMV fHbp KO. 5 μg of each NOMV were loaded. The
location of different proteins is indicated by the arrows. (B) Western blot to detect fHbp v.1 in NOMV from different mutants.
As controls, NOMV fHbp KO and NOMV from MenA wild type (expressing fHbp ID 5) were also loaded. 0.2 μg of NOMV
were loaded per lane. (C) Western blot for comparison of fHbp presence in NOMV from MenA wild type (expressing fHbp ID
5) and in NOMV OE ID 9. 0.05 to 0.5 μg of NOMV were loaded.
https://doi.org/10.1371/journal.pone.0181508.g002
Table 4. NOMV size characterisation by HPLC-SEC/MALS and dls.
MALS dls
Radius, nm Z-av (diameter, nm) (PdI)
NOMV OE ID 1 57.3 108.7 (0.331)
NOMV OE ID 5 53.6 91.8 (0.208)
NOMV OE ID 9 52.8 83.4 (0.145)
NOMV OE ID 74 56.0 106.9 (0.297)
https://doi.org/10.1371/journal.pone.0181508.t004
Contribution of fHbp sequence to cross-reactivity of meningococcal NOMV vaccines
PLOS ONE | https://doi.org/10.1371/journal.pone.0181508 July 25, 2017 9 / 21
Fig 3. Anti-fHbp IgG antibody levels in sera from mice immunised with NOMV or recombinant fHbp.
Anti-fHbp IgG antibody levels were measured in all immunisation groups against each of the 4 fHbp IDs. 1 μg/
mL of recombinant fHbp was used for ELISA plate coating. Mice were immunised twice, four weeks apart,
with 5 μg NOMV fHbp KO (A), or 1 μg NOMV OE one of the four different fHbp IDs (B-E), or with 20 μg
recombinant fHbp (F-I). Serum samples analysed were obtained 2 weeks after the second dose. Each symbol
Contribution of fHbp sequence to cross-reactivity of meningococcal NOMV vaccines
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Compared with mice immunised with NOMV OE fHbp, mice immunised with recombi-
nant fHbp consistently had IgG levels significantly higher when measured against the respec-
tive homologous fHbp sequences, than against any of the heterologous peptides (Fig 3F–3I).
This finding confirms that anti-fHbp IgG elicited by fHbp on NOMV, compared to recombi-
nant fHbp, are less specific for individual fHbp ID type and more broadly cross-reactive.
We investigated if there was a correlation between IgG levels against pairs of different fHbp
IDs, within each immunisation group. We found a correlation for 18 out of 24 comparisons
for the groups immunised with NOMV OE fHbp, and 20 out of 24 comparisons for the groups
immunised with recombinant fHbp. Correlation was not always reciprocal: in mice immu-
nised with NOMV OE ID 74, for example, IgG antibodies against fHbp ID 74 and against
fHbp ID 5 showed linear positive correlation (Pearson r = 0.76; p< 0.05), while this was not
true for sera from mice immunised with NOMV OE ID 5, when tested against the same anti-
gens (fHbp ID 5 and ID 74) (Fig 4; whole analysis in S2 Fig). Interestingly, sera from mice
immunised with NOMV OE ID 9 showed a correlation for only two out of six possible combi-
nations. The data indicate that different fHbp sequences induce antibodies with varying fine
specificities in relation to binding to different fHbp IDs.
SBA responses of mice immunised with NOMV with over-expressed
fHbp variant group 1 IDs or recombinant fHbp
We measured serum bactericidal antibody responses against diverse invasive meningococcal
strains (Table 3), carrying each of the four fHbp IDs over-expressed in NOMV or purified as
recombinant proteins, and carrying a heterologous PorA with respect to that present in the
NOMV vaccines. We measured SBA titres in single sera from individual mice in each immuni-
sation group (Fig 5, S3 Fig).
The MenC (ID 1) and MenA (ID 5) strains were susceptible to killing by sera raised against
NOMV fHbp KO. Nevertheless, against strains carrying fHbp ID 5 (MenA1, MenA2, and
MenA3) the highest SBA titres were induced by NOMV OE the homologous fHbp, even
though for MenA1 and MenA2 these were not statistically different from SBA induced by
NOMV OE ID 9.
Strains carrying fHbp ID 74 (MenX1 and MenX2) were resistant to sera raised against
NOMV fHbp KO, and susceptible to killing by sera from mice immunised with NOMV OE
each of the fHbp sequences (with the exception of MenX2, resistant to 6/8 sera raised against
NOMV OE ID 5), indicating that killing of these strains is only due to anti-fHbp antibodies.
Against both strains, the highest bactericidal responses were induced by NOMV OE homolo-
gous fHbp and fHbp ID 1, with titres significantly higher (p< 0.05) than those induced by
NOMV OE fHbp ID 5.
The MenW strain used in the SBAs, is a low expressor of fHbp ID 9, and was resistant to
killing by most of the mice sera tested. In contrast, the MenC strain carrying fHbp ID 1 was
susceptible to killing by 7/8 or 8/8 individual sera from each group.
In general, mice immunised with recombinant fHbp developed lower SBA responses, com-
pared to mice immunised with NOMV OE fHbp, with a higher number of mice showing no
detectable bactericidal activity. This was true for all the meningococcal strains tested, except
for MenC, which, as for the NOMV vaccines, was susceptible to killing by all sera.
represents a serum sample from an individual mouse; bars represent the geometric mean of each group.
Mann-Whitney test 2-tailed was performed to compare pairs of groups: * p < 0.05, ** p < 0.01, *** p < 0.001.
https://doi.org/10.1371/journal.pone.0181508.g003
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Since MenX strains were resistant to sera raised against NOMV fHbp KO, we investigated
whether a correlation exists between the SBA responses against these two strains and the anti-
fHbp ID 74 IgG ELISA units, in mice immunised with NOMV OE fHbp ID 74. We found no
correlation, suggesting that anti-fHbp IgG antibodies do not necessarily reflect the bactericidal
activity of the sera analysed (Fig 6).
Within each NOMV OE fHbp immunisation group, we compared bactericidal activity of
individual sera against the various meningococcal isolates. In many cases, there was an absence
of linear correlation between SBA titres against strains expressing different fHbp IDs, but we
did find correlation between SBA titres against strains with the same fHbp ID. For example, in
mice immunised with NOMV OE fHbp ID 1, SBA titres against two strains expressing either
ID 5 or ID 74 correlated, but SBA titres against two strains expressing different fHbp IDs (e.g.
one strain carrying ID 5 and one strain carrying ID 74) did not (Fig 7). The same was observed
with NOMV with OE fHbp ID 5 and 74. This suggests that at least a subset of the functional
antibodies elicited by NOMV OE fHbp target epitopes on fHbp that are ID-specific.
Discussion
Factor H binding protein (fHbp) is a meningococcal virulence factor that can be successfully
exploited as vaccine antigen [31, 32]. In mice, recombinant fHbp proteins generated antibod-
ies with functional fine specificities against strains carrying fHbp IDs with a different sequence
than the one used for immunisation; native outer membrane vesicles (NOMV) with over-
expressed fHbp, instead, induced antibodies with higher cross-reactivity [3, 5, 6, 10, 16, 17, 21,
22].
Immunogenicity of NOMV with over-expressed fHbp ID 1 and ID 9 has been tested in
mice in separate studies [21, 22, 33, 34]. However, no extensive analysis has been conducted so
far to elucidate the specific contribution that the fHbp sequence IDs over-expressed on
NOMV have on the generation of cross-reactive antibodies. We investigated the specificity
and cross-reactivity of anti-fHbp antibody response elicited by NOMV with over-expressed
different fHbp peptides belonging to variant group 1. Understanding the impact of fHbp
sequence on the specificity and cross-reactivity of the immune response generated by NOMV
OE fHbp, could guide the rational selection of a particular fHbp sub-variant to be expressed
Fig 4. Comparison of IgG antibody levels against different fHbp ID within the same immunisation
group. Comparison of IgG antibody levels against different recombinant fHbp IDs, in individual mice. Each
symbol represents an individual mouse, identified by a number; 1 μg/mL of recombinant fHbp was used for
ELISA plate coating. A) Mice immunised with NOMV OE ID 74 show linear correlation between anti-fHbp ID
74 IgG ELISA units (X axis) and anti-fHbp ID 5 IgG ELISA units (Y axis), by the Pearson Correlation test. B)
Mice immunised with NOMV OE ID 5 do not show linear correlation between anti-fHbp ID 5 IgG ELISA units
(X axis) and anti-fHbp ID 74 IgG ELISA units (Y axis).
https://doi.org/10.1371/journal.pone.0181508.g004
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Fig 5. Serum bactericidal responses induced in individual mice immunised with NOMV or
recombinant fHbp. Mice were immunised twice with NOMV (A-E), or with recombinant fHbp (F-I), four weeks
apart, as described in the materials and methods. Serum samples obtained two weeks after the second dose
were tested against a set of seven strains, expressing the four different fHbp ID types: ID 1 (●), ID 5 (▲), ID 9
(■), or ID 74 (▼). Each symbol represents the reciprocal titre of an individual mouse; horizontal bars represent
geometric mean titres of the group.
https://doi.org/10.1371/journal.pone.0181508.g005
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on NOMV, in order to broaden the potential coverage of a candidate vaccine. In the past, this
relationship was investigated for recombinant fHbp: cross-reactivity induced by recombinant
fHbp against strains expressing fHbp ID belonging to the same variant group is influenced by
the ID sequence [3]. In particular, bactericidal activity induced by fHbp decreases with increas-
ing genetic distance between fHbp sub-variant in the vaccine and on the strain tested [35], and
IDs more central located by phylogenetic analysis can elicit broader cross-protective bacteri-
cidal responses, compared to IDs that are more peripheral [36]. However, analysing the entire
fHbp sequence, and its variability among the different IDs, may not generate adequate infor-
mation for our investigation: with such analysis, variations at positions not necessarily immu-
nologically relevant are taken into consideration. Therefore, without discounting that other
parts of fHbp, and their variations, can be important as targets of bactericidal antibodies, we
Fig 6. Correlation of IgG antibody levels against recombinant ID 74 and SBA titres against MenX
strains. Each symbol represents a single mouse immunised with recombinant fHbp ID 74 and identified by a
number. No linear correlation was evident according to the Pearson Correlation test.
https://doi.org/10.1371/journal.pone.0181508.g006
Fig 7. Correlation of SBA titres against different strains, in mice immunised with NOMV OE ID 1. Each
symbol represents the reciprocal SBA titre of a mouse, identified by a number. According to the Pearson
Correlation test, linear correlation is present between SBA titres against strains carrying the same fHbp ID, but
not between SBA titres against strains carrying different fHbp ID.
https://doi.org/10.1371/journal.pone.0181508.g007
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chose to focus our attention on the surface-exposed amino acids of fHbp involved in factor H
(fH) binding. We hypothesized that variations in this region of the molecule are more critical
for the generation of cross-reactive antibodies, compared to variations of amino acids in other
part of the protein, and not surface-exposed; such consideration was also suggested for recom-
binant fHbp [36]. As a consequence, it is possible that there is a fH-contact sequence that is
conserved among different fHbp IDs, and that contributes to eliciting anti-fHbp antibodies
with extensively broad ID cross-reactivity. Our analysis revealed a consensus sequence of the
whole fH-binding site that is identical in 22% of the known fHbp ID sequences at the time of
the analysis.
We tested the immunogenicity in mice of NOMV derived from an African W meningococ-
cal strain, devoid of wild type v.2 fHbp and capsule biosynthesis, and over-expressing one out
of four different fHbp v.1 ID types (ID 1, ID 5, ID 9, or ID 74), relevant among currently circu-
lating African invasive isolates and/or expressed in NOMV in previous studies [16, 21, 30].
Among the fHbp IDs selected, ID 9 contained the fH-binding site consensus sequence.
NOMV OE fHbp induced similar anti-fHbp antibody levels compared to recombinant
fHbp, even if the amount of fHbp administered with the NOMV vaccines was more than 230
times lower than that administered as recombinant protein. Nevertheless, each of the NOMV
OE fHbp vaccines induced higher and broader serum bactericidal antibodies compared to the
equivalent recombinant proteins; one element that may contribute to such an outcome is a
synergistic effect of the antibodies against the wide range of antigens present on NOMV (e.g.
PorA, PorB, Opa/Opc, FbpA, FetA, NadA [37–40]). In mice immunised with recombinant
fHbp, Pajon et al. [16] observed high SBA responses against strains expressing the identical ID
used for immunisation, but lower cross-reactivity against strain with different IDs, even if
belonging to the same variant group. Against the MenA and MenX strains we observed similar
trends, although we recorded lower SBA titres. It is remarkable that a considerable number of
mice immunised with recombinant fHbp did not develop antibodies with serum bactericidal
activity against most meningococcal strains tested. These mice are not non-responders, as evi-
dent from the ELISA data: they have developed anti-fHbp antibodies, but these antibodies are
unable to kill meningococci efficiently. Intrinsic differences in the ability of the strains to sur-
vive in sera, especially combined with diverse fHbp expression levels, may contribute to differ-
ences reported here compared with other studies. For example, the MenW strain used in the
SBAs expressed very low levels of fHbp, likely explaining its resistance to killing by sera con-
taining antibodies targeted to fHbp.
Nevertheless, our data indicate that anti-fHbp IgG ELISA titres do not reflect the bacteri-
cidal activity of the sera, even when such activity appears to be dependent on anti-fHbp anti-
bodies. This lack of linear correlation contrasts to what has been observed in adult humans for
anti-DOMV IgG [41, 42] and anti-serogroup C capsule IgG [43]. Several factors may account
for this difference: i) differences between human and murine immune system; ii) antibodies
directed towards a wider range of antigens elicited by NOMV compared to DOMV; iii) the dif-
ferent nature of the antigens themselves, particularly in the case of MenC polysaccharide and
fHbp (a polysaccharide and a protein, respectively). The fact that anti-fHbp IgG antibodies
elicited by NOMV do not necessarily reflect the bactericidal activity of sera following immuni-
sation with NOMV, perhaps highlights the breadth of protective antigens present on NOMV.
In contrast, the lack of correlation between ELISA for fHbp and SBA when bacterial killing
appears only to be dependent on anti-fHbp antibodies, is surprising. This suggests that fHbp
can elicit an IgG antibody response against non-protective epitopes not only when adminis-
tered as recombinant proteins, but also when presented on NOMV.
Nevertheless, compared to recombinant fHbp, fHbp on NOMV appears to be able to elicit
antibodies directed against protective epitopes, not only present on the homologous ID
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peptide, but also on heterologous ID peptides. An important consideration in relation to this
is the presentation of antigens on NOMV in a more native environment and native conforma-
tion, compared to recombinant proteins, so that the epitopes on the NOMV vaccines better
resemble those of the bacterium. Moreover, the intrinsic adjuvanticity of outer membrane ves-
icles is also relevant [44, 45]: the immune response against protective antigens on NOMV is
likely to be enhanced due to the stimulation of innate receptors (e.g. TLR2 by PorB, TLR4 by
LOS [46, 47]), and may also be affected by a different balance in IgG subtype induced by
NOMV OE fHbp, compared to the recombinant protein [48].
Most meningococcal vaccine studies analyse the serum bactericidal response against N.
meningitidis testing pools of sera. However, with this kind of analysis, it is not possible to
appreciate individual differences, which become hidden in the pools, resulting in potentially
misleading immune response readouts. Therefore, we performed the SBA assays by testing sin-
gle mouse sera. This approach, however, had the consequence of only being able to test a lim-
ited number of strains in SBAs (because of resource constraints), and with rabbit, not human,
complement (because of the large amount of complement required). Nevertheless, we can now
appreciate small differences in the anti-fHbp antibody response generated by similar but dif-
ferent vaccine antigens, as well as the individual variations in response within groups of ani-
mals. These results suggest that even when expressed on NOMV, where plenty of other
antigens contribute to the bactericidal response elicited, the fHbp sequence has an impact on
the cross-reactivity of the antibodies induced. We did not expect anti-PorA (P1.5,2) antibodies
generated by the NOMV vaccines to contribute to SBA activity against the strains tested, as
these were chosen to have heterologous PorA molecules. Data confirmed this, also in the case
of different variant regions (VR) belonging to the same family, between the PorA of the tested
strain and the one of the vaccine: the MenX strains expressing PorA VR1 5–1 were completely
resistant to killing by antibodies against NOMV fHbp KO, and the group W strain expressing
PorA VR2 2–36 was resistant to most of the sera raised against the NOMV vaccines (likely sec-
ondary to low amounts of fHbp expression by this strain). SBA results suggest that each fHbp
ID over-expressed on NOMV elicits bactericidal antibodies directed towards ID-specific epi-
topes on the fHbp molecule that differ for different ID types. This is consistent with ELISA
results, which indicate that some fHbp IDs induce antibodies against more conserved and
shared epitopes of the fHbp molecule, while others induce antibodies against more variable
epitopes.
Our data do not show an obvious correlation between similarities in the fH-contact
sequence of the fHbp over-expressed on NOMV, and breadth of cross-reactive antibodies gen-
erated. However, the overall high antibody responses induced by NOMV OE fHbp and serum
bactericidal activity elicited by NOMV fHbp KO represent a limitation: they mask small differ-
ences in magnitude and functionality of antibody responses to fHbp generated among immu-
nisation groups. Moreover, as the IDs selected for over-expression differ not only in the fH-
binding site, but also in other parts of the protein sequence, the dissection of the specific rele-
vance of fH-contact residues is not straightforward. Therefore, it would be informative to engi-
neer investigational NOMV vaccines, expressing fHbp IDs with different fH-binding sites, but
identical with respect to the rest of the fHbp amino acid sequence. Another interesting
approach would be to expand the analyses to residues of fHbp surrounding fH-contact site. In
this regard, however, our analysis already has considered, among fH-contact residues, extra
amino acids, with respect to previous studies [49].
In conclusion, our study confirms that, in contrast to recombinant fHbp, NOMV OE fHbp
generate a broad bactericidal antibody response that is able to kill heterologous strains of
meningococcus. Differences in the fHbp sequence expressed on NOMV can contribute to dif-
ferent fine specificities in the antibody response generated. We provide a new structure-
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sequence approach for the rational selection of fHbp IDs to be used in NOMV-based vaccines,
focusing attention on functional surface-exposed regions. Focusing on common motives in
surfaced-exposed crucial sites, could be valuable for elucidating the contribution of other pro-
tective antigens to the cross-reactivity against meningococcal strains, elicited by outer mem-
brane vesicles. This would be extremely valuable for the design of future native outer
membrane vaccines. Finally, the same technology could be applied to the development of
other vaccines.
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